Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guobang PharmaSHSE:605507 +0.06%88 Net Margin % is 10.56% as of Mar. 2026, which is 20% below its 10-year median of 13.27. GuruFocus rates SHSE:605507 with a GF Score™ of 88/100 and a GF Value™ of ¥16.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Guobang Pharma ranks better than 72.74% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Guobang Pharma's Net Income for the
three
months ended in Mar. 2026 was ¥161 Mil. Guobang Pharma's Revenue for the
three
months ended in Mar. 2026 was ¥1,521 Mil. Therefore, Guobang Pharma's net margin for the quarter that ended in Mar. 2026 was 10.56%.
The historical rank and industry rank for Guobang Pharma's Net Margin % or its related term are showing as below:
SHSE:605507'
s Net Margin % Range Over the Past 10 Years
Min: 6.12 Med: 13.27 Max: 19.26
Current: 12.58
SHSE:605507's Net Margin % is ranked better than 72.74% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.47
vs SHSE:605507: 12.58
Guobang Pharma (SHSE:605507) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Guobang Pharma Net Margin % Related Terms
Guobang Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Guobang Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guobang Pharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Guobang Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guobang Pharma (SHSE:605507) has a Net Margin % of 10.56% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Guobang Pharma and its competitors. This is 20% below median its historical median of 13.27. Over the past decade, Guobang Pharma's Net Margin % has ranged from 6.12 to 19.26. According to the industry distribution chart, Guobang Pharma ranks #262 out of 961 companies in the Drug Manufacturers industry, placing it in the top 27.3%.
Is Guobang Pharma's Net Margin % too high?
Guobang Pharma's current Net Margin % of 10.56% is 20% below median its 10-year median of 13.27. Over the past 10 years, this metric has ranged from a low of 6.12 to a high of 19.26. The Drug Manufacturers industry median Net Margin % is 5.47. Guobang Pharma's value of 10.56% is 93.1% above this industry median. Based on the distribution chart, Guobang Pharma ranks #262 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guobang Pharma has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Guobang Pharma ranks #262 out of 961 companies for Net Margin %. This puts Guobang Pharma in the upper half of its industry. The industry median Net Margin % is 5.47. Guobang Pharma's value of 10.56% is 93.1% above this benchmark. Historically, Guobang Pharma's own Net Margin % has ranged from 6.12 to 19.26 over the past decade. While the company's 10-year median is 13.27 vs. the industry median of 5.47, Guobang Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.47, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guobang Pharma's current Net Margin % of 10.56% is 93.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Guobang Pharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guobang Pharma's current Net Margin % is 10.56%, which is 20% below median its own 10-year median of 13.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.00, compared to a current price of ¥16.30 — trading 1.9% above its estimated fair value. The current Net Margin % is 10.56%, which is 20% below median its 10-year median of 13.27 and 93.1% above the Drug Manufacturers industry median of 5.47. Guobang Pharma's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current Net Margin % is 10.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guobang Pharma (SHSE:605507) Overvalued in 2026?
Based on GuruFocus' analysis, Guobang Pharma stock appears to be overvalued.
The current stock price of ¥16.30 is trading 1.9% above its estimated GF Value™ of ¥16.00.
GuruFocus considers Guobang Pharma to be Fairly Valued.
Key valuation signals for SHSE:605507:
Net Margin %: 10.56% (20% below median its 10-year median of 13.27)
GF Value™: ¥16.00 vs. price of ¥16.30 (1.9% above fair value)
Industry Position: 93.1% above the Drug Manufacturers median (#262 of 961)
No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
88GF Score
Get the complete analysis for SHSE:605507
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605507 has been successfully added to your 
